Interview
with Neil Love, MD Breast Cancer Update for Medical Oncologists,
Program 6 2000
Play
Audio Below:
Dr.
Osborne: After the data that we had with the two big randomized
trials against Arimidex, which, itself, looks as good or better
than tamoxifen, and other aromatase inhibitors look as good or better
than tamoxifen, and with the results of the tamoxifen metastatic
randomized trial that should be coming out next summer, that will,
of course, be important. But I think there is reason enough to hypothesize
that it could be a better anti-tumor agent.
Dr.
Love: What about combinations of Faslodex and other endocrine interventions?
Any that sort of intuitively make sense?
Dr.
Osborne: Well, I think a lot of them might. I think particularly
intriguing would be an aromatase inhibitor plus Faslodex. There,
you’re doing two things. You’re getting rid of a ligand,
estradiol, or at least you’re reducing it down to a very low
level, and you’re depleting the receptor. So, that might theoretically
be a better way of treating patients. So, that would be an interesting
combination.
Formestane
is feasible and effective in elderly breast cancer patients with
comorbidity and disability. Venturino,
A.; Comandini, D.; Granetto, C.; Audisio, R. A.; Castiglione, F.;
Rosso, R., and Repetto, L. (Reprint available from: Venturino A
PO S Lazzaro, Via P Belli 26 I-12051 Alba CN Italy). Breast Cancer
Research & Treatment. 62(3):217-222, 2000 Aug. In process
Critique
of survival update analysis from two phase III anastrozole clinical
trials. Buzdar, A. U.; Wood; Wolter; Vogel; Bland, and Ravdin. Annals
of Surgical Oncology. 6(8 Suppl S):8S-11S, 1999 Dec. No abstract
Letrozole:
Which dose to be used? Buzdar, A. U. Journal of Clinical Oncology. 18(8):1802-1803,
2000 Apr. No abstract
Similarities
and distinctions in the mode of action of different classes of antioestrogens
[Review]. Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview. Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Treatment
with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis
factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Smolnikar,
K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available
from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl
Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research &
Treatment. 63(3):249-259, 2000 Oct. In process
Symposium
overview: Estrogens and antiestrogens in managing the patient with
breast cancer. Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary,
S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson
Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX
77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep.
In process
